Page 89 - Immunization Practices News Today

Bringing Taiwan to the World and the World to Taiwan

Taipei, June 27 (CNA) Several changes to co-payments for emergency care and prescription drugs covered by Taiwan's National Health Insurance (NHI) program will take effect on July 1.

Vaccines developed by Pfizer and GSK are expected to be approved by the full CDC by this fall, when cases of RSV tend to increase.

Bringing Taiwan to the World and the World to Taiwan

The CDC's advisory committee recommended this month that adults over 60 can receive one of two RSV vaccines, setting the stage for wide distribution this year.

Vaccines for a common but sometimes dangerous virus are well on the way to reaching the public. This month, outside experts assembled by the Centers for Disease Control and Prevention gave their blessing to two vaccines developed against the respiratory syncytial virus, or RSV. The vaccines, approved for older adults, are expected to be available in the U.S. by this fall.

GSK's Shingrix receives updated indication in Japan for the prevention of shingles

(CTN News) - The Centers for Disease Control and Prevention (CDC) is expected to vote on Wednesday on whether to recommend the..........

Nathan Posner/Anadolu Agency via Getty Images(WASHINGTON) -- A respiratory syncytial virus, or RSV, vaccine for older adults could soon be available after an advisory committee for the Centers for Disease Control and Prevention voted to recommend them Wednesday. During a meeting, the agencys Advisory Committee on Immunization Practices looked at clinical trial data for two vaccines, one by Pfizer and the other by GSK. Short of a full recommendation, the committee said adults aged 60 and over may...

Nathan Posner/Anadolu Agency via Getty Images(WASHINGTON) -- A respiratory syncytial virus, or RSV, vaccine for older adults could soon be available after an advisory committee for the Centers for Disease Control and Prevention voted to recommend them Wednesday. During a meeting, the agencys Advisory Committee on Immunization Practices looked at clinical trial data for two vaccines, one by Pfizer and the other by GSK. Short of a full recommendation, the committee said adults aged 60 and over may...